The August 2026 review in Pharmaceuticals found clascoterone 1% cream, a skin-applied androgen blocker, cuts inflammatory and non-inflammatory lesions with local side effects. For teens 12 and older with inflammatory acne, it offers a hormonal-pathway option usable by both boys and girls. Clascoterone 1% cream, sold as Winlevi, is the drug behind the finding. According to Drugs.com's FDA history, regulators approved it August 26, 2020 for acne vulgaris in patients 12 years and older (FDA history for Winlevi).
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How does it calm inflammatory acne?
- How strong is the benefit for red breakouts?
- Which teens is it for?
- What limits and combinations matter?
How does it calm inflammatory acne?
Clascoterone blocks DHT and androgen receptors inside sebaceous glands and sebocytes. That action lowers sebum and pro-inflammatory cytokines, according to the August 2026 review in Pharmaceuticals (August 2026 review in Pharmaceuticals).
It then breaks down quickly to inactive cortexolone, which limits whole-body exposure. The result is a local hormonal effect where acne starts, not a body-wide hormone shift.
How strong is the benefit for red breakouts?
In two 1,440-patient Phase 3 trials, treatment success reached 18.4-20.3% with clascoterone versus 6.5-9.0% with vehicle at 12 weeks. Inflammatory lesions fell about 46.2% versus about 32.5%, according to JAMA Dermatology data reported via Penn State (JAMA Dermatology data reported via Penn State).
That gain is modest, so clear skin is not typical with the cream alone. The American Academy of Dermatology's February 2024 guidelines list topical clascoterone as a conditional option. Core choices remain topical benzoyl peroxide, retinoids, and antibiotic combinations.
Which teens is it for?
Unlike pills that block hormones body-wide, this cream fits both male and female patients 12 and older. That breadth matters because teen boys lack many hormone-pathway choices, according to a Dove Medical Press review.
Benefit covered both inflammatory and non-inflammatory lesions in the review. Dermatologists match it to lesion type and severity.
- Age 12 or older with acne vulgaris
- Inflammatory breakouts, including moderate-to-severe cases
- Male or female patient seeking a skin-applied hormone-pathway action
What limits and combinations matter?
FDA labeling warns of HPA-axis suppression and hyperkalemia. According to the FDA label summary, transient HPA suppression occurred in 3 of 42 subjects age 12 and older (7.1%).
For moderate-to-severe inflammatory acne, dermatologists report pairing twice-daily clascoterone with nightly adapalene 0.3%. That regimen reached 65% clear or almost-clear at 16 weeks with good tolerability, according to Duke data reported by AJMC (Duke findings reported by AJMC).
You Might Also Like
- Omega-3 Balance and Acne Questions in the 2026 Diet Review: Associations, Trials, and Evidence Gaps for Teens With Acne
- Mediterranean and Vegan Diet Claims in the 2026 Acne Review: What the Evidence Means for Teens With Acne
- Limited Topical Spironolactone Evidence in the 2026 Review: What Researchers Still Need to Learn for Adults With Persistent Acne